Related Experiment Video
Updated: Mar 22, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity
Peihong Liu1, Yongli Du1, Lianhua Song1
1School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353, China.
Abstract:
Protein tyrosine phosphatase 1B (PTP1B) as a key negative regulator of both insulin and leptin receptor pathways has been an attractive therapeutic target for the treatment of type 2 diabetes mellitus (T2DM) and obesity. With the goal of enhancing potency and selectivity of the PTP1B inhibitors, a series of methyl salicylate derivatives as ABC type PTP1B inhibitors (P1-P7) were discovered. More importantly, compound P6 exhibited high potent inhibitory activity (IC50 = 50 nM) for PTP1B with 15-fold selectivity over T-cell PTPase (TCPTP). Further studies on cellular activities revealed that compound P6 could enhance insulin-mediated insulin receptor β (IRβ) phosphorylation and insulin-stimulated glucose uptake.
Insights
Researchers developed novel methyl salicylate derivatives as potent inhibitors of protein tyrosine phosphatase 1B (PTP1B). Compound P6 shows high efficacy and selectivity, offering potential for type 2 diabetes and obesity treatments.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Protein tyrosine phosphatase 1B (PTP1B) is a key negative regulator of insulin and leptin signaling pathways.
- Dysregulation of PTP1B is implicated in type 2 diabetes mellitus (T2DM) and obesity.
- Developing selective PTP1B inhibitors is crucial for therapeutic intervention.
Purpose of the Study:
- To discover and optimize novel methyl salicylate derivatives as potent and selective PTP1B inhibitors.
- To evaluate the inhibitory activity and selectivity of these compounds against PTP1B.
- To assess the cellular effects of the lead compound on insulin signaling and glucose uptake.
Main Methods:
- Synthesis of a series of methyl salicylate derivatives (P1-P7) designed as ABC-type PTP1B inhibitors.
- In vitro enzymatic assays to determine inhibitory concentrations (IC50) and selectivity against PTP1B and T-cell PTPase (TCPTP).
- Cellular assays to measure insulin receptor β (IRβ) phosphorylation and insulin-stimulated glucose uptake.
Main Results:
- Compound P6 demonstrated potent inhibition of PTP1B with an IC50 of 50 nM.
- Compound P6 exhibited significant selectivity, showing 15-fold higher potency against PTP1B compared to TCPTP.
- In cellular studies, compound P6 enhanced insulin-mediated IRβ phosphorylation and insulin-stimulated glucose uptake.
Conclusions:
- Methyl salicylate derivatives represent a promising class of PTP1B inhibitors.
- Compound P6 is a highly potent and selective PTP1B inhibitor with potential therapeutic applications for T2DM and obesity.
- Compound P6's ability to modulate insulin signaling pathways warrants further investigation for metabolic disease treatment.
Related Concept Videos
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Inhibition of Cdk Activity
ABC Transporters: Exporter

